Breakthrough in Treatment for Type 1 Diabetes with Artificial Intelligence

A wearable, autonomous blood sugar device certified by the U.S. Food and Drug Administration (FDA) is using artificial intelligence to help treat type 1 diabetes, adapting to each patient’s individual changing insulin needs.

The iLet Bionic Pancreas System by Beta Bionics has been granted Breakthrough Device Designation status from the FDA. The status is given to medical devices that provide particularly effective treatment for life-threatening diseases.

“We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” says Beta Bionics President and CEO Ed Damiano. “We are particularly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”

The system requires no more than a user’s body weight to control blood glucose levels automatically. Unlike other therapy methods, users of the iLet Bionic Pancreas do not need to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.